On March 3, 2021 Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, reported its technology showcases at the recent American Association of Cancer Research ("AACR") 2021 meeting (Press release, Kiromic, MAY 3, 2021, View Source [SID1234579026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kiromic BioPharma is using cutting-edge artificial intelligence (AI) technology to select biomarkers to develop CAR-T therapy for solid tumors.

The Company believes that the use of AI will enable it to compress development timelines in ways which are not achievable by its peers who are not equipped with AI technology.

The American Association of Cancer Research recognized Kiromic’s innovation with its acceptance of 6 poster presentations at the recent conference on April 9-14, 2021.

Kiromic’s 6 posters showcased the company’s following technology platforms and advances:

CancerDiff, a deep data mining engine that harmonizes billions of data points across disease types and states, data types, data structures and data platforms and Diamond AI, a proprietary system which combs through billions of transcription data points across public and private RNA databases to present the best immunogenic peptide candidates for CAR-T;
CancerSplice, the Company’s 3D, isoform prediction engine, which examines billions of data points to select the best targets;
Validation of the Company’s AI technology in identifying NY-ESO-1, which is a very well-known target and served as an excellent validation of the Company’s engine’s accuracy;
Our company also demonstrated that our chPD1 receptor is effective on solid tumors in both in vitro and in vivo models with minimal toxicities;
We showed that our non-viral gene edit technology could have the same target specificity of Cas9 without the DNA destruction common to HIV integrase;
Finally we investigated NK as a potential adoptive cell therapy platform for CAR-T.
Dr. Maurizio Chiriva, PhD stated that, "Our mission is to become the leader in allogenic, off-the-shelf CAR-T in solid tumors. Our cutting-edge AI engine for biomarker identification and selection will support our development pathway going forward. We believe that our ability to deliver allogenic, off-the-shelf CAR-T for solid tumors is within reach and that our therapy will offer patients higher efficacy at lower costs. We expect to make this therapy a reality this year."

Mr. Gianluca Rotino, the Company’s Chief Strategy and Innovation Officer, noted that, "We are proud to have set a new record for the number of posters accepted for a single company by the prestigious American Association of Cancer Research (AACR 2021), who accepted 6 of our posters. These poster presentations also broke ground for the number of new technologies that Kiromic is bringing to the world of live-cell therapy (CAR-T).

"We believe that we are disrupting the industry with our innovative approach as summarized in the following table:

Kiromic’s approach

Industry standard

Targeting

AI driven and machine learning bio-informatics for targeting

Classic chemistry

Live Cell Type

Gamma Delta T cells for CAR-T

Peers’ NK, or Mesenchymal (stem cells)

Donor Tissue Type

Allogenic gamma delta T cells from healthy donors

Marketed therapies’ autologous T-cells from frail patients

Gene Editing

Non-viral, non-destructive to DNA

Industry standard CRISPR Cas9

GMP Manuf.

In-house Vivarium and GMP manufacturing for our clinical trials

Industry standard of using external Contract Manufacturers

"With these innovations, we believe that we are poised to lead the future for CAR-T in solid tumors. We expect to build on this lead with planned in-human dosing in the third quarter of 2021."

ABOUT KIROMIC POSTERS AT AACR (Free AACR Whitepaper) 2021

Session

Focus

Poster

Link to Poster at AACR (Free AACR Whitepaper)

BSB01.05

New Software for Data Analysis

247

Identification of an ovarian cancer selective splice variant of mesothelin utilizing the Kiromic proprietary search engine CancerDiff

CancerDiff:

Our deep data-mining engine which harmonizes billions of data points across:

— disease types and states

— data types,

— data structures, and

— data platforms.

Diamond AI:

Our system which combs through billions of transcription data points across public and private RNA databases to present the best immunogenic peptide candidates for CAR-T.

PO.IM02.01

Adoptive Cell Therapy

1534

Mesothelin isoform 2 is a novel target for allogenic CARγδT cell therapy in solid tumors

CancerSplice:

Our 3D, isoform prediction engine which examines billions of data points to select the best targets.

BSB01.04

New Algorithms

243

Identification of novel epitopes of NY-ESO-1 for solid malignancies by Kiromic proprietary search engine Diamond

NY-ESO-1:

How we got to NY-ESO-1 using our AI target selection engine. NY-EOS-1 is a very well-known target and served as an excellent validation of our engine’s accuracy.

PO.ET08.01

Gene and Vector-Based Therapy

1154

Site-specific gene editing with ABBIE for T-cell therapy

ABBIE:

We showed that our non-viral gene edit technology could have the same target specificity of Cas9 without the DNA destruction common to HIV integrase.

PO.IM02.01

Adoptive Cell Therapy

LB148

Gamma delta T cells engineered with a chimeric PD-1 receptor effectively control PD-L1 positive tumors in vitro and in vivo with minimal toxicities.

chPD1:

We demonstrated that our chPD1 receptor was effective on solid tumors in both in vitro and in vivo models with minimal toxicities.

PO.IM02.01

Adoptive Cell Therapy

1535

Allogenic CAR iNKT as a cell therapy platform targeting tumor antigen Isomesothelin

iNKT:

We investigated NK as a potential adoptive cell therapy platform for CAR-T.

About AACR (Free AACR Whitepaper) (American Association of Cancer Research)